Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sequential Myeloablative Autologous Stem Cell Transplantation Followed by Allogeneic Non-Myeloablative Stem Cell Transplantation for Patients With Poor Risk Lymphomas

NCT01181271 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT01181271
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01181271 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sequential Myeloablative Autologous Stem Cell Transplantation Followed by Allogeneic Non-Myeloablative Stem Cell Transplantation for Patients With Poor Risk Lymphomas
Lead sponsor
Massachusetts General Hospital
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2010
Completion date
February 29, 2016
Enrollment
42 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia, diffuse, large b-cell, lymphoma, hodgkin's lymphoma, lymphoma, low-grade, lymphoma, small lymphocytic, mantle-cell lymphoma, t-cell lymphoma